Cellectar Historical Balance Sheet

CLRB Stock

USD 1.46 0.06 3.95%

Trend analysis of Cellectar Biosciences balance sheet accounts such as Other Current Liab of 7.6 M, Total Current Liabilities of 13.6 M or Property Plant And Equipment Net of 1.1 M provides information on Cellectar Biosciences' total assets, liabilities, and equity, which is the actual value of Cellectar Biosciences to its prevalent stockholders. By breaking down trends over time using Cellectar Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cellectar Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cellectar Biosciences is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

About Cellectar Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cellectar Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Cellectar Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cellectar Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cellectar currently owns. An asset can also be divided into two categories, current and non-current.

Cellectar Biosciences Balance Sheet Chart

At present, Cellectar Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 7.6 M, whereas Total Stockholder Equity is projected to grow to (1.3 M).

Total Assets Total Current Liabilities Property Plant And Equipment Net Net Debt Accounts Payable Liabilities And Stockholders Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Cellectar Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cellectar Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cellectar Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cellectar Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Accounts Payable

An accounting item on the balance sheet that represents Cellectar Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cellectar Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Most accounts from Cellectar Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cellectar Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.At present, Cellectar Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 7.6 M, whereas Total Stockholder Equity is projected to grow to (1.3 M).

	2021	2022	2023	2024 (projected)
Cash	35.7M	19.9M	9.6M	13.3M
Accounts Payable	1.4M	2.6M	5.6M	5.9M

Cash Accounts Payable

Cellectar Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Non Current Liabilities Total	Current Deferred Revenue	Short Term Debt	Short Long Term Debt Total	Other Liab	Other Assets
Total Assets		-0.02	0.04	0.95	-0.33	-0.99	-0.38	0.11	0.99	-0.4	-0.09	0.99	0.31	0.17	0.82	0.5	0.03	-0.39	0.99	0.38	-0.26	0.44	-0.2	-0.23	0.41	0.51
Other Current Liab	-0.02		0.93	-0.31	0.13	0.05	-0.64	0.65	-0.01	-0.05	-0.31	-0.01	0.33	0.75	0.04	0.57	0.93	0.44	-0.01	-0.02	-0.21	0.56	-0.21	-0.14	0.35	-0.03
Total Current Liabilities	0.04	0.93		-0.29	-0.02	-0.01	-0.83	0.87	0.05	-0.2	-0.28	0.05	0.32	0.91	0.18	0.76	1.0	0.36	0.06	-0.11	-0.25	0.67	-0.25	-0.17	0.52	0.06
Total Stockholder Equity	0.95	-0.31	-0.29		-0.32	-0.95	-0.1	-0.19	0.93	-0.33	-0.01	0.93	0.19	-0.14	0.73	0.23	-0.3	-0.5	0.93	0.39	-0.17	0.2	-0.11	-0.17	0.24	0.47
Property Plant And Equipment Net	-0.33	0.13	-0.02	-0.32		0.42	0.31	-0.17	-0.42	0.9	0.3	-0.42	0.21	-0.14	-0.6	-0.35	0.01	0.9	-0.42	0.2	-0.34	-0.19	-0.42	-0.31	-0.38	-0.43
Net Debt	-0.99	0.05	-0.01	-0.95	0.42		0.38	-0.08	-1.0	0.49	0.15	-1.0	-0.27	-0.15	-0.85	-0.5	0.0	0.48	-1.0	-0.34	0.2	-0.44	0.13	0.17	-0.43	-0.52
Retained Earnings	-0.38	-0.64	-0.83	-0.1	0.31	0.38		-0.87	-0.41	0.49	0.25	-0.41	-0.31	-0.91	-0.54	-0.99	-0.82	-0.01	-0.42	0.11	0.37	-0.81	0.35	0.3	-0.8	-0.22
Accounts Payable	0.11	0.65	0.87	-0.19	-0.17	-0.08	-0.87		0.13	-0.29	-0.16	0.13	0.34	0.94	0.33	0.82	0.87	0.23	0.14	-0.12	-0.19	0.62	-0.21	-0.14	0.56	0.23
Cash	0.99	-0.01	0.05	0.93	-0.42	-1.0	-0.41	0.13		-0.49	-0.15	1.0	0.29	0.19	0.85	0.53	0.05	-0.45	1.0	0.34	-0.21	0.47	-0.14	-0.18	0.44	0.51
Non Current Assets Total	-0.4	-0.05	-0.2	-0.33	0.9	0.49	0.49	-0.29	-0.49		0.51	-0.49	0.08	-0.33	-0.64	-0.52	-0.17	0.77	-0.5	0.17	-0.31	-0.47	-0.38	-0.31	-0.49	-0.3
Non Currrent Assets Other	-0.09	-0.31	-0.28	-0.01	0.3	0.15	0.25	-0.16	-0.15	0.51		-0.15	0.17	-0.2	-0.23	-0.24	-0.26	0.21	-0.15	0.24	-0.03	-0.1	-0.08	-0.05	-0.21	-0.2
Cash And Short Term Investments	0.99	-0.01	0.05	0.93	-0.42	-1.0	-0.41	0.13	1.0	-0.49	-0.15		0.29	0.19	0.85	0.53	0.05	-0.45	1.0	0.34	-0.21	0.47	-0.14	-0.18	0.44	0.51
Common Stock Total Equity	0.31	0.33	0.32	0.19	0.21	-0.27	-0.31	0.34	0.29	0.08	0.17	0.29		0.45	0.27	0.33	0.34	0.3	0.29	0.78	0.02	0.47	-0.04	0.09	0.0	0.13
Common Stock Shares Outstanding	0.17	0.75	0.91	-0.14	-0.14	-0.15	-0.91	0.94	0.19	-0.33	-0.2	0.19	0.45		0.35	0.88	0.91	0.24	0.2	-0.01	-0.15	0.79	-0.15	-0.08	0.53	0.07
Other Current Assets	0.82	0.04	0.18	0.73	-0.6	-0.85	-0.54	0.33	0.85	-0.64	-0.23	0.85	0.27	0.35		0.63	0.16	-0.53	0.85	0.37	-0.15	0.46	-0.07	-0.14	0.58	0.55
Other Stockholder Equity	0.5	0.57	0.76	0.23	-0.35	-0.5	-0.99	0.82	0.53	-0.52	-0.24	0.53	0.33	0.88	0.63		0.76	-0.06	0.54	-0.04	-0.38	0.82	-0.35	-0.32	0.79	0.28
Total Liab	0.03	0.93	1.0	-0.3	0.01	0.0	-0.82	0.87	0.05	-0.17	-0.26	0.05	0.34	0.91	0.16	0.76		0.39	0.05	-0.09	-0.26	0.68	-0.27	-0.19	0.51	0.04
Property Plant And Equipment Gross	-0.39	0.44	0.36	-0.5	0.9	0.48	-0.01	0.23	-0.45	0.77	0.21	-0.45	0.3	0.24	-0.53	-0.06	0.39		-0.46	0.12	-0.34	0.05	-0.42	-0.28	-0.24	-0.41
Total Current Assets	0.99	-0.01	0.06	0.93	-0.42	-1.0	-0.42	0.14	1.0	-0.5	-0.15	1.0	0.29	0.2	0.85	0.54	0.05	-0.46		0.33	-0.21	0.47	-0.15	-0.18	0.44	0.52
Common Stock	0.38	-0.02	-0.11	0.39	0.2	-0.34	0.11	-0.12	0.34	0.17	0.24	0.34	0.78	-0.01	0.37	-0.04	-0.09	0.12	0.33		0.06	0.14	0.04	0.08	-0.19	0.12
Non Current Liabilities Total	-0.26	-0.21	-0.25	-0.17	-0.34	0.2	0.37	-0.19	-0.21	-0.31	-0.03	-0.21	0.02	-0.15	-0.15	-0.38	-0.26	-0.34	-0.21	0.06		-0.11	0.99	0.99	-0.54	-0.18
Current Deferred Revenue	0.44	0.56	0.67	0.2	-0.19	-0.44	-0.81	0.62	0.47	-0.47	-0.1	0.47	0.47	0.79	0.46	0.82	0.68	0.05	0.47	0.14	-0.11		-0.11	-0.02	0.52	-0.08
Short Term Debt	-0.2	-0.21	-0.25	-0.11	-0.42	0.13	0.35	-0.21	-0.14	-0.38	-0.08	-0.14	-0.04	-0.15	-0.07	-0.35	-0.27	-0.42	-0.15	0.04	0.99	-0.11		0.98	-0.5	-0.15
Short Long Term Debt Total	-0.23	-0.14	-0.17	-0.17	-0.31	0.17	0.3	-0.14	-0.18	-0.31	-0.05	-0.18	0.09	-0.08	-0.14	-0.32	-0.19	-0.28	-0.18	0.08	0.99	-0.02	0.98		-0.52	-0.2
Other Liab	0.41	0.35	0.52	0.24	-0.38	-0.43	-0.8	0.56	0.44	-0.49	-0.21	0.44	0.0	0.53	0.58	0.79	0.51	-0.24	0.44	-0.19	-0.54	0.52	-0.5	-0.52		0.4
Other Assets	0.51	-0.03	0.06	0.47	-0.43	-0.52	-0.22	0.23	0.51	-0.3	-0.2	0.51	0.13	0.07	0.55	0.28	0.04	-0.41	0.52	0.12	-0.18	-0.08	-0.15	-0.2	0.4

Click cells to compare fundamentals

Cellectar Biosciences Account Relationship Matchups

Cellectar Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.3M	58.7M	37.2M	21.6M	12.1M	16.0M
Other Current Liab	(127.0)	2.0M	2.3M	2.9M	7.3M	7.6M
Total Current Liabilities	2.8M	3.6M	4.0M	5.5M	12.9M	13.6M
Total Stockholder Equity	9.1M	54.8M	33.0M	15.5M	(1.4M)	(1.3M)
Property Plant And Equipment Net	783.9K	638.3K	549.1K	979.0K	1.6M	1.1M
Net Debt	(10.1M)	(56.7M)	(35.4M)	(19.3M)	(9.0M)	(9.5M)
Retained Earnings	(111.7M)	(126.8M)	(150.9M)	(179.5M)	(217.5M)	(206.6M)
Accounts Payable	1.3M	1.4M	1.4M	2.6M	5.6M	5.9M
Cash	10.6M	57.2M	35.7M	19.9M	9.6M	13.3M
Non Current Assets Total	865.1K	719.6K	630.3K	1.1M	1.6M	2.0M
Cash And Short Term Investments	10.6M	57.2M	35.7M	19.9M	9.6M	13.3M
Common Stock Total Equity	167.0	47.0	94.0	454.0	408.6	448.7
Common Stock Shares Outstanding	767.5K	2.0M	5.6M	7.1M	12.2M	12.8M
Liabilities And Stockholders Equity	12.3M	58.7M	37.2M	21.6M	12.1M	16.0M
Other Current Assets	771.0K	1.5M	1.7M	663.2K	888.2K	785.0K
Other Stockholder Equity	119.6M	161.5M	182.6M	193.6M	211.4M	222.0M
Total Liab	3.2M	3.9M	4.2M	6.1M	13.4M	14.1M
Property Plant And Equipment Gross	783.9K	356.0K	549.1K	979.0K	2.5M	2.6M
Total Current Assets	11.4M	57.9M	36.6M	20.5M	10.5M	14.0M
Accumulated Other Comprehensive Income	(5.8M)	(181.2K)	(309.4K)	(1.4M)	(1.6M)	(1.7M)
Common Stock	47.0	94.0	454.0	611.0	207.0	196.65
Non Current Liabilities Total	421.6K	301.7K	166.3K	553.0K	494.0K	469.3K
Current Deferred Revenue	965.1K	1.4M	2.0M	2.4M	2.8M	2.9M
Short Term Debt	105.9K	119.9K	270.9K	101.7K	59.0K	56.0K
Short Long Term Debt Total	527.5K	421.6K	301.7K	603.8K	553.0K	487.8K
Property Plant Equipment	435.1K	356.0K	549.1K	979.0K	881.1K	1.2M
Retained Earnings Total Equity	(84.3M)	(97.6M)	(111.7M)	(126.8M)	(114.1M)	(108.4M)
Preferred Stock Total Equity	995.8K	2.5M	1.1M	20.0M	23.0M	24.2M
Net Tangible Assets	7.9M	34.8M	31.7M	14.1M	16.2M	13.6M
Capital Surpluse	94.1M	108.3M	119.6M	161.5M	185.8M	103.4M
Capital Lease Obligations	527.5K	421.6K	301.7K	603.8K	553.0K	580.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:

How To Invest In Cellectar

Details

Is Cellectar Stock a good investment?

Details

What is Cellectar Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.41)

Return On Assets

(1.66)

Return On Equity

(7.97)

The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cellectar Historical Balance Sheet

About Cellectar Balance Sheet Analysis

Cellectar Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Net Debt

Accounts Payable

Liabilities And Stockholders Equity

Cellectar Biosciences balance sheet Correlations

Cellectar Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cellectar Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.99	Retained Earnings
Net Debt	- 0.99	Total Assets
Net Debt	- 0.95	Total Stockholder Equity